Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;52(7):2335-9.
doi: 10.1128/AAC.01360-07. Epub 2008 Apr 14.

Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin

Affiliations

Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin

Kyriaki Kanellakopoulou et al. Antimicrob Agents Chemother. 2008 Jul.

Abstract

A biodegradable system of poly-D,L-dilactide releasing ciprofloxacin was assessed in a Pseudomonas aeruginosa osteomyelitis model after inoculation of the test pathogen into the left tibia of 76 New Zealand White rabbits; 31 were controls (group A), and 45 were implanted with the polymer at the infection site (group B). The rabbits were killed on a weekly basis, and cancellous bone was harvested for histopathology and for estimation of bacterial growth and the concentrations of ciprofloxacin. Tibial X ray was performed immediately before the animals were killed. The total number of fistulas with purulent discharge that developed after inoculation of the pathogen was counted, and fistulas with purulent discharge were found in 16 animals in group A (51.6%) and 3 animals in group B (6.7%) (P < 0.0001). The animals in group A had a profound loss of body weight compared to the animals in group B. The main radiological finding was the presence of sequestra in 25 animals (80.6%) in group A and 6 animals in group B (13.3%) (P < 0.0001). The bacterial load in group B was significantly reduced compared to that in group A, possibly due to the prolonged local antibiotic release at concentrations exceeding even 80 times the MIC for the test pathogen. The histology of animals killed after week 49 revealed a mild inflammatory reaction accompanied by diffuse fibrosis and new bone formation in group A animals and the presence of small polymer particles in group B animals. It is concluded that the system described achieved eradication of the pathogen, accompanied by clinical and radiologically confirmed benefits, so this treatment may be a candidate for the management of difficult orthopedic infections.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Changes in body weight in animals in groups A (controls; filled circles) and B (treatment; open squares) on the day that the animals were killed compared to the baseline body weight before bacterial challenge. Statistically significant differences are shown. pNS, P is not significant.
FIG. 2.
FIG. 2.
Growth of the Pseudomonas aeruginosa test isolate in animals in groups A (controls; filled circles) and B (treatment; open squares) on the day after infection.

References

    1. Dutt, M., and G. K. Khuller. 2001. Liposomes and PLG microparticles as sustained release antitubercular drug carriers: an in vitro-in vivo study. Int. J. Antimicrob. Agents 18:245-252. - PubMed
    1. Galanakis, N., H. Giamarellou, T. Moussas, and E. Dounis. 1997. Chronic osteomyelitis caused by multi-resistant gram(−) bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J. Antimicrob. Chemother. 39:241-246. - PubMed
    1. Gürsel, I., F. Korkusuz, F. Türesin, G. Alaeddinoğlu, and V. Harici. 2001. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 22:73-80. - PubMed
    1. Haas, D. W., and M. P. McAndrew. 1996. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am. J. Med. 101:550-561. - PubMed
    1. Hansen, G. T., X. Zhao, K. Drlica, and J. M. Blondeau. 2006. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 27:120-124. - PubMed

MeSH terms